EHS
EHS

Gene therapy for X-linked retinitis pigmentosa shows positive safety, efficacy data


October 02, 2022

1 min watch

Source:

Michaelides M. Ph1/2 AAV5-RPGR (botaretigene sparoparvovec) gene therapy trial in RPGR-associated X-linked retinitis pigmentosa (XLRP). Presented at: American Academy of Ophthalmology meeting; Sept. 30-Oct. 3, 2022; Chicago.

Disclosures:
Michaelides reports consulting for Janssen Pharmaceuticals and MeiraGTx and holding equity in MeiraGTx.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Michel Michaelides, MD, discusses study results from a gene therapy trial for RPGR-associated X-linked retinitis pigmentosa.

“We presented excellent safety and efficacy data both in terms of retinal sensitivity and, arguably more importantly, functional vision,” Michaelides said.



Source link

EHS
Back to top button